Retatrutide and MOTS-C: Exploring the Next Generation of Metabolic Research
Metabolic research is entering a new era.
Instead of examining weight regulation solely through calorie intake and energy expenditure, scientists are investigating the complex communication between the brain, digestive system, pancreas, liver, skeletal muscle, adipose tissue and mitochondria.
Two compounds attracting considerable scientific interest are Retatrutide and MOTS-C.
Retatrutide is an investigational triple-hormone receptor agonist being studied for obesity, type 2 diabetes and related metabolic conditions. MOTS-C is a naturally occurring mitochondrial-derived peptide being investigated for its potential role in cellular energy regulation, metabolic stress and insulin sensitivity.
Although Retatrutide and MOTS-C are frequently discussed within the same area of metabolic research, they are fundamentally different compounds. They act through different pathways, have reached different stages of clinical development and should not be presented as an established combination.
This article examines what Retatrutide and MOTS-C are, how researchers believe they work, what the available evidence shows and which questions remain unanswered.
What is Retatrutide?
Retatrutide, also known by the research identifier LY3437943, is an investigational peptide developed by Eli Lilly.
It is described as a triple-hormone receptor agonist because it activates three receptors involved in metabolic regulation:
- Glucagon-like peptide-1 receptor, or GLP-1R
- Glucose-dependent insulinotropic polypeptide receptor, or GIPR
- Glucagon receptor, or GCGR
This distinguishes Retatrutide from existing single- and dual-receptor medicines.
Semaglutide primarily activates the GLP-1 receptor. Tirzepatide activates both the GLP-1 and GIP receptors. Retatrutide adds glucagon receptor activity to create a three-receptor mechanism.
Researchers are investigating whether this approach can simultaneously influence appetite, insulin secretion, blood-glucose regulation and energy expenditure.
How does Retatrutide work?
Retatrutide has been engineered to interact with three metabolic hormone receptors. Each receptor has a different biological role.
GLP-1 receptor activity
GLP-1 is a hormone released from the digestive system after food is consumed. It participates in appetite regulation, gastric emptying and glucose-dependent insulin secretion.
Activation of the GLP-1 receptor may:
- Increase feelings of fullness
- Reduce appetite and energy intake
- Support glucose-dependent insulin release
- Reduce glucagon release when blood glucose is elevated
- Slow gastric emptying
This pathway is already used by several licensed medicines, although Retatrutide itself is not currently authorised in the UK.
GIP receptor activity
GIP is another hormone released in response to food. It is involved in insulin secretion, nutrient handling and adipose-tissue biology.
Researchers believe that combining GIP and GLP-1 receptor activity may produce metabolic effects that differ from activating GLP-1 alone. However, GIP biology is complex, and its effects may vary depending on metabolic state and the presence of other receptor signals.
Glucagon receptor activity
Glucagon is commonly associated with increasing blood glucose, but its wider role includes lipid metabolism, amino-acid metabolism and energy expenditure.
The glucagon component of Retatrutide is especially significant because it may contribute to increased energy expenditure and fat metabolism. At the same time, uncontrolled glucagon activity could increase glucose production.
Retatrutide’s combined GLP-1 and GIP activity is therefore intended to balance the metabolic effects of glucagon receptor activation.
Why is Retatrutide called a triple agonist?
An agonist is a substance that binds to and activates a biological receptor.
Retatrutide is called a triple agonist because one engineered molecule activates the GLP-1, GIP and glucagon receptors.
The purpose of this design is not simply to produce three separate effects. Researchers are studying whether coordinated receptor activity can produce a broader metabolic response than targeting one pathway in isolation.
For this reason, Retatrutide is also sometimes called:
- A triple-hormone receptor agonist
- A GIP, GLP-1 and glucagon receptor agonist
- A triple incretin agonist
- A triple-G compound
“Triple incretin” is not completely precise because glucagon is not normally classified as an incretin hormone. “Triple-hormone receptor agonist” is the more scientifically accurate description.
What does the Retatrutide research show?
Retatrutide has progressed through phase 2 studies and into a broad phase 3 clinical-development programme.
Retatrutide phase 2 obesity trial
A 2023 phase 2 trial published in The New England Journal of Medicine included adults with obesity or overweight and a weight-related condition, but without diabetes.
At 48 weeks, mean body-weight changes included:
- 17.1% reduction with the investigated 4 mg maintenance group
- 22.8% reduction with the 8 mg group
- 24.2% reduction with the 12 mg group
- 2.1% reduction with placebo
Among participants assigned to the 12 mg group:
- 100% achieved at least 5% weight reduction
- 93% achieved at least 10%
- 83% achieved at least 15%
These figures represent trial averages and response thresholds. They do not predict how an individual would respond, and they should not be interpreted as instructions for use.
The trial was funded by Eli Lilly, the developer of Retatrutide. Read the phase 2 study on PubMed.
Retatrutide phase 3 research
In May 2026, Eli Lilly announced topline findings from the TRIUMPH-1 phase 3 obesity trial.
At 80 weeks, reported mean body-weight reductions were:
- 19.0% with 4 mg
- 25.9% with 9 mg
- 28.3% with 12 mg
- 2.2% with placebo
In a study extension involving participants with a starting BMI of at least 35, the 12 mg group reportedly reached an average reduction of 30.3% at 104 weeks.
These were company-announced topline results. Full peer-reviewed analysis remains important for understanding the complete efficacy, safety, discontinuation and subgroup data. See the Lilly TRIUMPH-1 announcement.
Retatrutide and liver-fat research
A phase 2 substudy investigated Retatrutide in participants with elevated liver fat associated with metabolic dysfunction.
The research reported substantial reductions in liver-fat content, particularly among the higher-dose trial groups. These results have generated interest in Retatrutide research involving metabolic dysfunction-associated steatotic liver disease.
However, reduced liver fat in a clinical study does not establish that Retatrutide is an approved treatment for liver disease.
Retatrutide side effects and research limitations
The most commonly reported adverse events in Retatrutide trials have been gastrointestinal.
These have included:
- Nausea
- Diarrhoea
- Vomiting
- Constipation
- Reduced appetite
- Abdominal discomfort
Some studies have also observed dose-dependent increases in heart rate. Researchers continue to examine cardiovascular outcomes, tolerability, gallbladder-related events, pancreatic safety, changes in body composition and the implications of substantial long-term weight reduction.
It is also important to distinguish between supervised clinical-trial material and products sold online under the Retatrutide name. A label cannot confirm the identity, purity, concentration or sterility of an unregulated product.
Is Retatrutide available in the UK?
As of August 2026, Retatrutide is not authorised as a medicine in the United Kingdom.
The Medicines and Healthcare products Regulatory Agency has warned consumers against unauthorised products sold as Retatrutide. The agency states that products obtained outside legitimate clinical trials have not been assessed for safety, quality or effectiveness.
Licensed UK weight-management medicines include certain semaglutide, tirzepatide and liraglutide products when prescribed and supplied through appropriate regulated channels.
Retatrutide should not be confused with these authorised medicines. Read the current MHRA warning.
What is MOTS-C?
MOTS-C—usually styled scientifically as MOTS-c—is a short mitochondrial-derived peptide consisting of 16 amino acids.
Its name is derived from “mitochondrial open reading frame of the 12S rRNA type-c”.
MOTS-C is unusual because its genetic instructions originate within mitochondrial DNA rather than the nuclear DNA that contains most human genes.
Mitochondria are commonly described as the energy-producing structures of the cell. Modern research shows that they also function as signalling centres capable of communicating information about energy availability, oxidative stress and cellular health.
MOTS-C is being studied as one of these mitochondrial signals.
How does MOTS-C work?
Researchers are still determining the complete MOTS-C mechanism.
Laboratory evidence suggests that MOTS-C may influence cellular energy regulation by interacting with pathways associated with glucose metabolism, metabolic stress and gene expression.
MOTS-C and AMPK signalling
One pathway frequently associated with MOTS-C research is AMP-activated protein kinase, or AMPK.
AMPK acts as a cellular energy sensor. When cellular energy availability falls, AMPK helps coordinate processes that generate energy while limiting processes that consume large amounts of it.
Preclinical MOTS-C research has associated the peptide with:
- Increased AMPK activity
- Glucose utilisation
- Skeletal-muscle metabolism
- Cellular stress adaptation
- Metabolic homeostasis
This does not mean MOTS-C has been clinically proven to reproduce the effects of exercise or treat metabolic disease in humans.
Communication between mitochondria and the nucleus
MOTS-C may also participate in retrograde signalling—the process through which mitochondria communicate with the cell nucleus.
Under metabolic stress, research suggests that MOTS-C can move into the nucleus and influence the expression of genes involved in antioxidant defence and cellular adaptation.
This mitochondrial-to-nuclear communication is one of the reasons MOTS-C has attracted interest in ageing and longevity research.
MOTS-C, exercise and skeletal muscle
A 2021 study published in Nature Communications reported that naturally occurring MOTS-C levels increased following exercise in a small group of healthy male volunteers.
The same research found that externally administered MOTS-C improved physical performance and metabolic adaptation in mouse models of different ages.
The important distinction is that the human part of this research measured the body’s own MOTS-C response to exercise. The performance findings associated with administered MOTS-C came primarily from animal experiments.
It would therefore be inaccurate to claim that MOTS-C has been clinically proven to improve human exercise performance. Read the Nature Communications research.
MOTS-C and insulin sensitivity research
Early laboratory and animal research has examined whether MOTS-C influences glucose uptake and insulin sensitivity, particularly in skeletal muscle.
A foundational 2015 study reported that MOTS-C helped prevent diet-induced obesity and insulin resistance in mouse models. Subsequent research has continued to explore associations between circulating MOTS-C, ageing, obesity and type 2 diabetes.
These findings are scientifically interesting but remain predominantly preclinical.
A registered human study is now designed to investigate whether MOTS-C can improve insulin sensitivity in adults with prediabetes and overweight or obesity. Until controlled human trials report their results, conclusions about clinical effectiveness remain premature. View the registered MOTS-C study.
MOTS-C and longevity research
MOTS-C is frequently marketed online as a “longevity peptide”, but this description goes beyond the available human evidence.
Researchers are interested in MOTS-C because mitochondrial function, metabolic flexibility and cellular stress responses can change with age.
Animal and laboratory studies have explored possible relationships with:
- Age-related physical decline
- Mitochondrial function
- Muscle homeostasis
- Oxidative stress
- Inflammation
- Metabolic resilience
There is currently no high-quality evidence demonstrating that administered MOTS-C extends human lifespan or prevents age-related disease.
For scientific accuracy, MOTS-C should be described as a mitochondrial-derived peptide under investigation—not as a proven anti-ageing treatment.
For a closer look at MOTS-C alongside the synthetic mitochondrial peptide SS-31, see our guide to MOTS-C and SS-31 mitochondrial research.
Retatrutide vs MOTS-C: what is the difference?
Retatrutide and MOTS-C belong to very different areas of metabolic research.
| Research area | Retatrutide | MOTS-C |
|---|---|---|
| Compound type | Engineered peptide triple agonist | Naturally occurring mitochondrial-derived peptide |
| Primary pathways | GLP-1, GIP and glucagon receptors | Mitochondrial signalling, AMPK and stress-response pathways |
| Main research interest | Obesity, glucose regulation and metabolic disease | Cellular energy regulation, insulin sensitivity and ageing biology |
| Human evidence | Phase 2 studies and multiple phase 3 trials | Limited human observational and early interventional research |
| UK authorisation | Not authorised | Not authorised as a medicine |
| Established combination | No | No |
Retatrutide directly targets hormone receptors involved in appetite and systemic metabolism. MOTS-C is being studied as a mitochondrial signal that may affect how cells respond to energy demand and metabolic stress.
They should not be treated as interchangeable compounds.
Can Retatrutide and MOTS-C be combined?
There is currently no robust clinical evidence establishing the safety or effectiveness of combining Retatrutide and MOTS-C.
A theoretical difference in mechanism does not demonstrate compatibility. Combining investigational compounds could produce unexpected effects involving:
- Blood-glucose regulation
- Insulin sensitivity
- Appetite and food intake
- Gastrointestinal function
- Energy expenditure
- Cardiovascular responses
- Nutritional status and body composition
No validated Retatrutide and MOTS-C combination protocol has been established through controlled human trials.
Claims that MOTS-C can enhance Retatrutide, prevent specific side effects or preserve lean mass during Retatrutide-associated weight reduction should be treated as speculative unless supported by appropriate clinical evidence.
The future of Retatrutide and MOTS-C research
Retatrutide and MOTS-C demonstrate two very different directions in modern metabolic science.
Retatrutide represents the development of engineered multi-receptor agonists designed to influence several interconnected metabolic systems with a single molecule.
MOTS-C represents the growing recognition that mitochondria do more than produce cellular energy. They also generate signals that may help cells respond to exercise, nutritional changes, metabolic stress and ageing.
Future Retatrutide research will need to clarify:
- Long-term safety and tolerability
- Cardiovascular outcomes
- Weight maintenance after treatment
- Effects on lean and fat mass
- Outcomes in different metabolic conditions
- How it compares directly with authorised treatments
Future MOTS-C research will need to establish:
- Whether preclinical findings translate to humans
- Pharmacokinetics and appropriate research administration
- Short- and long-term safety
- Effects on insulin sensitivity and glucose metabolism
- Whether administered MOTS-C produces meaningful clinical outcomes
- How endogenous MOTS-C differs from externally administered material
Both compounds are scientifically important. However, their levels of evidence are not equivalent, and neither justifies unsupported claims about untested combinations or guaranteed outcomes.
Frequently asked questions
What is Retatrutide?
Retatrutide is an investigational peptide that activates the GLP-1, GIP and glucagon receptors. It is being studied for obesity, type 2 diabetes and related metabolic conditions.
Is Retatrutide the same as Mounjaro?
No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. Retatrutide is an investigational triple agonist targeting GIP, GLP-1 and glucagon receptors.
Is Retatrutide approved in the UK?
No. As of August 2026, Retatrutide is not authorised as a medicine in the UK.
What is MOTS-C?
MOTS-C is a 16-amino-acid peptide encoded within mitochondrial DNA. It is being studied for its potential role in energy metabolism, insulin sensitivity, cellular stress responses and age-related metabolic changes.
Is MOTS-C a GLP-1 peptide?
No. MOTS-C does not work as a GLP-1 receptor agonist. It is a mitochondrial-derived signalling peptide studied through different metabolic pathways.
Is MOTS-C proven to cause weight loss?
No. Laboratory and animal studies have produced interesting findings, but there is insufficient controlled human evidence to describe MOTS-C as an effective weight-loss treatment.
Can Retatrutide and MOTS-C be used together?
There is no established human clinical evidence confirming that combining Retatrutide and MOTS-C is safe or effective.
Are Retatrutide and MOTS-C licensed medicines?
Neither Retatrutide nor MOTS-C is currently authorised as a medicine in the United Kingdom.
NŪVO Research Perspective
The emerging science surrounding Retatrutide and MOTS-C highlights the complexity of metabolism.
Receptor signalling, mitochondrial communication, glucose regulation, skeletal-muscle biology and energy balance form an interconnected network. Understanding that network requires controlled research, transparent reporting and a clear separation between preliminary findings and clinically proven outcomes.
NŪVO will continue to examine developments in peptide and metabolic research while prioritising scientific accuracy, responsible communication and evidence-led education. Browse the research catalogue — every compound is supplied for laboratory research only.
Research and medical disclaimer
This article is provided for general educational and scientific-information purposes only. It does not constitute medical advice, diagnosis, treatment guidance or a recommendation to obtain or use any compound.
Retatrutide is investigational and is not currently authorised for use in the United Kingdom. MOTS-C is not an approved UK medicine. Products labelled for laboratory research must not be presented as medicines or used for self-treatment.
Anyone considering medical weight-management support should consult an appropriately qualified healthcare professional and obtain licensed medicines only through regulated channels.
Sources
- Jastreboff AM et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. The New England Journal of Medicine, 2023.
- Eli Lilly. TRIUMPH‑1 Phase 3 topline results, May 2026.
- UK Medicines and Healthcare products Regulatory Agency. No summer shortcut for safe weight loss, July 2026.
- Lee C et al. The mitochondrial-derived peptide MOTS‑c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
- Kraus D et al. Nicotinamide N‑methyltransferase knockdown protects against diet-induced obesity. Nature, 2014.